Skip to main content
SpringerLink
Log in

Type 1 IGF receptor in human breast diseases

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

The first step of the action of IGF1 and IGF2 (IGFs) is their binding to membrane receptors. IGF binding sites have been characterized by competitive binding and cross-linking techniques in human breast cancer cell lines as well as in human breast cancers and in human benign breast diseases. IGF2 is a good competitor of125I-IGF1 binding to IGF1-R; insulin competes but with a potency 1/100 lower than the IGF1 potency. Chemical cross-linking experiments revealed that the apparent molecular weight of the IGF1-binding sites is 130,000. Alpha IR-3, a murine monoclonal antibody against the IGF1-R, blocks IGF1-binding to this receptor. This antibody inhibits the IGF1-stimulated growth of breast cancer cells. Therefore, the IGF1 specific binding sites correspond to the previously described type 1 IGF receptors (IGF1-R) in normal tissues. Cross-linking experiments with labeled IGF2 resulted in a major band of apparent Mr 260,000–270,000 that was inhibited by unlabeled IGF2 but not by insulin, and corresponds to the type 2 IGF receptor; a second band of apparent Mr 130,000 was inhibited by excess IGFs and insulin (Type I receptor). The alpha-IR3 inhibition of the IGF2 mitogenic activity suggest that IGF1-R partially mediates the growth effect of IGF2 in these cells.

We and others have demonstrated that most breast cancer cell lines contain IGF1-R. This is also the case in breast cancer biopsies in which histo-autoradiographic analyses allowed the localization of IGF1-R on the epithelial component. IGF1-R concentrations were positively correlated to estradiol and progesterone receptor concentrations. In our experience, the presence of IGF1-R is associated with a better prognosis. Finally, IGF1-R are found less frequently and at lower concentrations in benign breast diseases. These results suggest that IGF1-R could be a marker of the proliferative epithelial component within the tumor.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Moses AC, Pilistine SJ: Insulin-like growth factors control of animal cell proliferation.In Boynton AL, Leffert HL (eds) Control of Animal Cell Proliferation, Vol I. Academic Press, New York, 1985, pp 91–120

    Google Scholar 

  2. Rosenfeld RG, Hintz RL: Somatomedin receptors function and regulation.In Conn PM (ed) The Receptors, Vol 3. Academic Press, New York, 1988, pp 281–329

    Google Scholar 

  3. Peyrat JP, Bonneterre J, Dusanter-Fourt I, Leroy-Martin B, Djiane J, Demaille A: Characterization of insulin-like growth factor 1 receptors (IGF1-R) in human breast cancer cell lines. Bull Cancer 76:311–319, 1989

    PubMed  Google Scholar 

  4. Pollak MN, Polychronakos C, Yousefi S, Richard M: Characterization of insulin-like growth factor I (IGF-I) receptors of human breast cancer cells. Biochem Biophys Res Commun 154:326–331, 1988

    PubMed  Google Scholar 

  5. De Leon DD, Bakker B, Wilson DM, Hintz RL, Rosenfeld RG: Demonstration of insulin-like growth factor (IGF-1 and -2) receptors and binding protein in human breast cancer cell lines. Biochem Biophys Res Commun 152:398–405, 1988

    PubMed  Google Scholar 

  6. Furlanetto RW, Di Carlo JN: Somatomedin-C receptors and growth effects in human breast cells maintained in long-term tissue culture. Cancer Res 44:2122–2128, 1984

    PubMed  Google Scholar 

  7. Myal Y, Shiu RPC, Bhaumick B, Bala M: Receptor binding and growth promoting activity of insulin-like growth factor in human breast cancer cells (T47-D) in culture. Cancer Res 44:5486–5490, 1984

    PubMed  Google Scholar 

  8. Osborne CK, Coronado EB, Kitten LJ, Arteaga CL, Fuqua SAW, Marshall M, Li CH: Insulin-like growth factor-II (IGFII): a potential autocrine /paracrine growth factor for human breast cancer acting via the IGF1 receptor. Mol Endocrinol 3:1701–1709, 1989

    PubMed  Google Scholar 

  9. Stewart AJ, Johnson MD, May FEB, Westley BR: Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human brest cancer cells. J Biol Chem 265:21172–21178, 1990

    PubMed  Google Scholar 

  10. Freiss G, Rochefort H, Vignon F: Mechanism of 4-hydroxytamoxifen anti-growth factor activity in breast cancer cells: alterations of growth factor receptor binding sites and tyrosine kinase activity. Biochem Biophys Res Commun 173:919–926, 1990

    PubMed  Google Scholar 

  11. Mathieu M, Rochefort H, Barenton B, Prebois C, Vignon F: Interactions of cathepsin-D and insulin-like growth factor-II (IGF-II) on the IGF-II/ mannose-6-phosphate receptor in human breast cancer cells and possible consequences on mitogenic activity of IGF-II. Mol Endocrinology 4:1327–1335, 1990

    Google Scholar 

  12. Kull FC, Jacobs S, Su Y-F, Svoboda ME, Van Wyck JJ, Cuatrecasas P: Monoclonal antibody to receptor for insulin and somatomedin-C. J Biol Chem 258:6561–6566, 1983

    PubMed  Google Scholar 

  13. Jacobs S, Cook S, Svoboda ME, Van Wyck JJ: Interaction of the monoclonal antibodies alpha-IR1 and alpha-IR3 with insulin and somatomedin-C receptors. Endocrinology 118:223–226, 1986

    PubMed  Google Scholar 

  14. Rohlik QT, Adams D, Kull FC, Jacobs S: An antibody to the receptor for IGF I inhibits the growth of MCF-7 cells in tissue culture. Biochem Biophys Res Commun 149:276–281, 1987

    PubMed  Google Scholar 

  15. Arteaga CL, Osborne CK: Growth inhibition of human breast cancer cellsin vitro with an antibody against the type I somatomedin receptor. Cancer Res 49:6237–6241, 1989

    PubMed  Google Scholar 

  16. Arteaga CL, Kitten LJ, Coronado EB, Jacobs S, Kull FC, Allred DC, Osborne CK: Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest 84:1418–1423, 1989

    PubMed  Google Scholar 

  17. Cullen KJ, Yee D, Sly WS, Perdue J, Hampton B, Lippman ME, Rosen N: Insulin-like growth factor receptor expression and function in human breast cancer. Cancer Res 50:48–53, 1990

    PubMed  Google Scholar 

  18. Ullrich A, Gray A, Tam AW, Yang-Feng T, Tsubokawa M, Collins C, Henzel W, Le Bon T, Kathuria S, Chen E, Jacobs S, Franke U, Ramachandran J, Fujita-Yamaguchi Y: Insulin-like growth factor 1 receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J 5:2503–2512, 1986

    PubMed  Google Scholar 

  19. Papa V, Hartmann KKP, Rosenthal SM, Maddux BA, Siiteri PK, Goldfine ID: Progestins induce down-regulation of insulin-like growth factor I (IGFI) receptors in human breast cancer cells: potential autocrine role of IGF-II. Mol Endocrinol 5:709–717, 1991

    PubMed  Google Scholar 

  20. Peyrat JP, Bonneterre J, Beuscart R, Djiane J, Demaille A: Insulin-like growth factor I receptor (IGF1-R) in human breast cancer. Relation to estradiol and progesterone receptors. Cancer Res 48:6429–6433, 1988

    PubMed  Google Scholar 

  21. Pekonen F, Partanen S, Mäkinen T, Rutanen EM: Receptors for epidermal growth factor and insulin-like growth factor I and their relation to steroid receptors in human breast cancer. Cancer Res 48:1343–1347, 1988

    PubMed  Google Scholar 

  22. Peyrat J-Ph, Jammes H, Ban E, Haour F, Edery M, Djiane J, Bonneterre J: Insulin-like growth factor 1 receptors (IGF1-R) in human breast tumors: histo-autoradiographic analysis (HAA) and mRNA expression. Proc Amer Soc Cancer Res 31:49 (Abstr 292), 1990

    Google Scholar 

  23. Bonneterre J, Peyrat JP, Beuscart R, Demaille A: Prognostic significance of insulin-like growth factor 1 receptors in human breast cancer. Cancer Res 50:6931–6935, 1990

    PubMed  Google Scholar 

  24. Pollak MN, Perdue JF, Margolese RG, Baer K, Richard M: Presence of somatomedin receptors on primary human breast and colon carcinomas. Cancer Letters 38:223–230, 1987

    PubMed  Google Scholar 

  25. Foekens JA, Portengen H, Van Putten WLJ, Trapman AMAC, Reubi JC, Alexieva-Figusch J, Klijn JGM: Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. Cancer Res 49:7002–7009, 1989

    PubMed  Google Scholar 

  26. Berns EMJJ, Klijn JGM, Van Stavaren IL, Portengen H, Foekens JA: Sporadic amplification of the insulin-like growth factor 1 receptor gene in human breast tumors. Cancer Res 52:1036–1039, 1992

    PubMed  Google Scholar 

  27. Peyrat JP, Bonneterre J, Laurent JC, Louchez MM, Amrani S, Leroy-Martin B, Vilain MO, Delobelle A, Demaille A: Presence and characterization of insulin-like growth factor 1 receptors in human benign breast disease. Eur J Cancer Clin Oncol 24:1425–1431, 1988

    PubMed  Google Scholar 

  28. Bonneterre J, Peyrat JP, Laurent JC, Jammes H, Hecquet B, Vilain MO, Demaille A: Prolactin receptors (PRL-R), insulin-like growth factor receptors (IGF1-R) and IGF1 plasma level in benign breast disease. Cancer Detec Prev, in press, 1992

  29. Haour F, Dussaillant M, Leblanc P, Rostene W: Mise en évidence et répartition topographique des récepteurs du LH-RH chez le rat mâle normal et castré au niveau du système nerveux central. C R Acad Sci Paris 305:41–42, 1987

    PubMed  Google Scholar 

  30. Peyrat JP, Bonneterre J, Vennin Ph, Louchez MM, Fournier C, Hecquet B, Lefebvre J, Demaille A: Insulin-like growth factor 1 (IGF1) plasma concentration in breast cancer (BC) patients. Proc Amer Soc Cancer Res:31:50 (Abstr 295), 1990

    Google Scholar 

  31. Vennin Ph, Peyrat JP, Bonneterre J, Louchez MM, Harris AG, Demaille A: Effect of the long-acting somatostatin analogue SMS 201-995 (Sandostatin) in advanced breast cancer. Anticancer Res 9:153–156, 1989

    PubMed  Google Scholar 

  32. Bonneterre J, Mauriac L, Weber B, Roche H, Fargeot P, Tubiana-Hulin M, Sevin M, Chollet P, Cappelaere P: Tamoxifen plus bromocriptine versus tamoxifen plus placebo in advanced breast cancer: results of a double blind multicentre clinical trial. Eur J Cancer Clin Oncol 24:1851–1853, 1988

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratoire d'Endocrinologie Expérimentale, Centre Oscar Lambret, BP 307, 59020, Lille, France

    J. Ph. Peyrat & J. Bonneterre

Authors
  1. J. Ph. Peyrat
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Bonneterre
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Peyrat, J.P., Bonneterre, J. Type 1 IGF receptor in human breast diseases. Breast Cancer Res Tr 22, 59–67 (1992). https://doi.org/10.1007/BF01833334

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01833334

Key words

Search

Navigation